Bioconjugation of Supramolecular Metallacages to Integrin Ligands for Targeted Delivery of Cisplatin

Han, J., Rader, A., Reichart, F., Aikman, B., Wenzel, M. N., Woods, B., Weinmüller, M., Ludwig, B. S., Sturup, S., Groothuis, G. M. M., Permentier, H. P., Bischoff, R., Kessler, H., Horvatovich, P. & Casini, A., 21-Nov-2018, In : BIOCONJUGATE CHEMISTRY. 29, 11, p. 3856-3865

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard



Cisplatin occupies a crucial role in the treatment of various malignant tumours. However, its efficacy and applicability are heavily restricted by severe systemic toxicities and drug resistance. Our study exploits the active targeting of supramolecular metallacages to enhance the activity of cisplatin in cancer cells while reducing its toxicity. Thus, Pd2L4 cages (L = ligand) have been conjugated to four integrin ligands with different binding affinity and selectivity. Cage formation and encapsulation of cisplatin was proven by NMR spectroscopy. Upon encapsulation, cisplatin showed increased cytotoxicity in vitro, in melanoma A375 cells overexpressing αvβ3 integrins. Moreover, ex vivo studies in tissue slices indicated reduced toxicity towards healthy liver and kidney tissues for cage-encapsulated cisplatin. Analysis of metal content by ICP-MS demonstrated that encapsulated drug is less accumulated in these organs compared to the 'free' one.

Original languageEnglish
Pages (from-to)3856-3865
Issue number11
Early online date2018
Publication statusPublished - 21-Nov-2018

Download statistics

No data available

ID: 66960690